RBC Capital analyst Rishi Jaluria upgrades NICE (NASDAQ:NICE) from Sector Perform to Outperform and announces $300 price target.
HC Wainwright & Co. Downgrades Galera Therapeutics to Neutral
HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Galera Therapeutics (NASDAQ:GRTX) from Buy to Neutral.